Table 2. Ongoing studies evaluating adjuvant immunotherapy.

Trial	N	Estimated completion date	NCT number
Adjuvant nivolumab in resected lung cancers – a randomized phase III study of nivolumab after surgical resection and adjuvant chemotherapy in treating patients with stage IB-IIIA non-small cell lung cancer (ANVIL)	903	July 2024	NCT02595944
Study of pembrolizumab (MK-3475) versus placebo for participants with non-small cell lung cancer after resection and completion of standard adjuvant therapy (PEARLS)	1080	February 2024	NCT02504372
Double blind placebo-controlled study of adjuvant MEDI4736 in completely resected NSCLC (BR.31)	1360	Enero 2024	NCT02273375
Study to assess safety and efficacy of atezolizumab (MPDL3280A) compared with best supportive care following chemotherapy in patients with lung cancer (IMpower010)	1280	December 2027	NCT02486718
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, ALCHEMIST Chemo-IO Study	1263	December 2024	NCT04267848
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)	8300	September 2021	NCT02194738